DNA · NYSE
Ginkgo Bioworks Holdings (DNA) Stock Price & Fundamentals
Ginkgo Bioworks Holdings (DNA) closed at $662.10 on Oct 9, 2026, up 0.89% from the previous close of $656.24.
Share price, past year
1Y +12.34%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $662.10 |
| Sep 30, 2026 | $654.54 |
| Aug 31, 2026 | $629.47 |
| Jul 31, 2026 | $615.55 |
| Jun 30, 2026 | $593.28 |
| May 29, 2026 | $589.88 |
| Apr 30, 2026 | $597.22 |
| Mar 31, 2026 | $649.99 |
| Feb 27, 2026 | $609.06 |
| Jan 30, 2026 | $625.10 |
| Dec 31, 2025 | $634.67 |
| Nov 28, 2025 | $599.15 |
| Oct 31, 2025 | $575.25 |
Key statistics
- Market cap
- $42.18B
- P/E (TTM)
- —
- EPS (TTM)
- −$5.64
- Revenue (TTM)
- $132.42M
- Net income (TTM)
- −$290.80M
- Shares outstanding
- 63.7M
- Dividend yield
- —
- 52-week range
- $558.26 – $662.10
Ginkgo Bioworks Holdings's market cap is $42.18B, based on a share price of $662.10 and 63.7M shares outstanding as of Jun 30, 2026.
Financials
Ginkgo Bioworks Holdings reported revenue of $170.16M for fiscal 2025, down 25.06% from fiscal 2024.
Ginkgo Bioworks Holdings reported a net loss of $312.76M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $170.16M | −25.1% | −$312.76M | −183.8% | −$5.64 | −$178.72M |
| FY2024ended Dec 31, 2024 | $227.04M | −9.7% | −$547.03M | −240.9% | −$10.54 | −$382.13M |
| FY2023ended Dec 31, 2023 | $251.46M | −47.4% | −$892.87M | −355.1% | −$18.37 | −$336.30M |
| FY2022ended Dec 31, 2022 | $477.71M | +52.2% | −$2.10B | −440.6% | −$50.20 | −$304.47M |
| FY2021ended Dec 31, 2021 | $313.84M | +309.4% | −$1.83B | −583.1% | −$55.60 | −$310.34M |
| FY2020ended Dec 31, 2020 | $76.66M | +41.5% | −$126.61M | −165.2% | −$4.00 | −$193.65M |
| FY2019ended Dec 31, 2019 | $54.18M | — | −$119.33M | −220.2% | −$4.00 | −$66.88M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $20.16M | −$46.71M | — |
| Q1 FY2026ended Mar 31, 2026 | $19.47M | −$82.59M | — |
| Q4 FY2025ended Dec 31, 2025 | $53.95M | −$80.75M | −$1.41 |
| Q3 FY2025ended Sep 30, 2025 | $38.84M | −$80.76M | −$1.45 |
| Q2 FY2025ended Jun 30, 2025 | $39.13M | −$60.30M | −$1.10 |
| Q1 FY2025ended Mar 31, 2025 | $38.23M | −$90.96M | −$1.68 |
| Q4 FY2024ended Dec 31, 2024 | $43.85M | — | −$1.91 |
| Q3 FY2024ended Sep 30, 2024 | $89.05M | −$56.40M | −$1.08 |
Company profile
- Name
- Ginkgo Bioworks Holdings, Inc.
- Ticker
- DNA
- Exchange
- NYSE
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 27 Drydock Avenue, 8th Floor, Boston, MA 02210
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001830214
Recent SEC filings
- Aug 6, 2026
- Aug 5, 2026
- Jul 30, 2026
- Jun 12, 2026
- May 7, 2026
- May 7, 2026
- Apr 7, 2026
- Feb 27, 2026
Frequently asked questions
What is Ginkgo Bioworks Holdings's stock price?
Ginkgo Bioworks Holdings (DNA) closed at $662.10 on Oct 9, 2026, up 0.89% from the previous close of $656.24.
What is Ginkgo Bioworks Holdings's market cap?
Ginkgo Bioworks Holdings's market cap is $42.18B, based on a share price of $662.10 and 63.7M shares outstanding as of Jun 30, 2026.
How much revenue does Ginkgo Bioworks Holdings make?
Ginkgo Bioworks Holdings reported revenue of $170.16M for fiscal 2025, down 25.06% from fiscal 2024.
Does Ginkgo Bioworks Holdings pay a dividend?
Ginkgo Bioworks Holdings's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Ginkgo Bioworks Holdings, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures